<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452385</url>
  </required_header>
  <id_info>
    <org_study_id>CM082-OPH-101</org_study_id>
    <nct_id>NCT02452385</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of CM082 in Patients With wAMD</brief_title>
  <official_title>Phase 1 Study of CM082 in Patients With wAMD: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AnewPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AnewPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and&#xD;
      Pharmacokinetics of CM082 tablets in Chinese Patients With wAMD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and&#xD;
      Pharmacokinetics of CM082 tablets in Chinese Patients With wAMD. Patients will receive one of&#xD;
      four doses for up to four weeks. Single/multiple dose pharmacokinetics in these patients will&#xD;
      be studied. At the end of four weeks, investigator will evaluate safety and tolerability and&#xD;
      decide whether to continue treatment for a total of six months to further evaluate safety and&#xD;
      preliminary efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Sponsor requirements&#xD;
  </why_stopped>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>six months</time_frame>
    <description>Incidence of the adverse event after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of CM082</measure>
    <time_frame>four weeks</time_frame>
    <description>Single/multiple dose pharmacokinetics in Chinese wAMD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in best corrected visual acuity (BCVA) (in number of letters)</measure>
    <time_frame>six months</time_frame>
    <description>Change from baseline in mean BCVA (ETDRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Central Retinal Thickness</measure>
    <time_frame>six months</time_frame>
    <description>Change from baseline in mean central retinal thickness (OCT)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>CM082 tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose of CM082 tablet starting at 25mg once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CM082 tablet</intervention_name>
    <description>CM082 tablets taken orally</description>
    <arm_group_label>CM082 tablet</arm_group_label>
    <other_name>X-82</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Active choroidal neovascularization (CNV) associated with AMD, as evidenced on&#xD;
             fluorescein angiography (FA) and OCT.&#xD;
&#xD;
          -  Patients with either no previous anti-VEGF therapy or prior anti-VEGF therapy with&#xD;
             evidence of response to treatment and the need for additional treatment.&#xD;
&#xD;
          -  Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA 20/40 to 20/320 in the study&#xD;
             eye(s).&#xD;
&#xD;
          -  Adequate bone marrow, hepatic, and renal functions.&#xD;
&#xD;
          -  Willing and able to provide written informed consent, comply with the investigational&#xD;
             study protocol and return for all study visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with Polypoidal Choroidal Vasculopathy (PCV) as evidenced on Indocyanine&#xD;
             Green Angiography (ICG).&#xD;
&#xD;
          -  Previous treatment with photodynamic therapy (PDT), external beam radiation, subfoveal&#xD;
             focal laser photocoagulation, submacular surgery, or transpupillary thermotherapy.&#xD;
&#xD;
          -  CNV due to causes other than AMD, including ocular histoplasmosis syndrome, angioid&#xD;
             streaks, multifocal choroiditis, choroidal rupture, or pathologic myopia.&#xD;
&#xD;
          -  Geographic atrophy involving the foveal center in the study eye.&#xD;
&#xD;
          -  Any retinal vascular disease or retinal degeneration other than AMD in the study eye.&#xD;
&#xD;
          -  Any significant disease in the study eye that could compromise best-corrected visual&#xD;
             acuity.&#xD;
&#xD;
          -  Cataract surgery in the study eye within three months of screening.&#xD;
&#xD;
          -  Trabeculectomy or aqueous shunt or valve in the study eye.&#xD;
&#xD;
          -  Use of any investigational agent or participation in any other clinical trial of an&#xD;
             investigational agent or investigational therapy within thirty (30) days of baseline.&#xD;
&#xD;
          -  Females of child bearing potential that are pregnant or not using medically acceptable&#xD;
             contraception; males unwilling to take adequate contraceptive measures.&#xD;
&#xD;
          -  Serious allergy to or prior significant adverse reaction to fluorescein.&#xD;
&#xD;
          -  Undiagnosed acute illness first observed during screening or between screening and&#xD;
             baseline, or severe concurrent medical conditions that, in the investigators judgment,&#xD;
             represent a safety concern.&#xD;
&#xD;
          -  Severe cardiac disease, symptomatic congestive heart failure, unstable angina, acute&#xD;
             coronary syndrome, myocardial infarction or coronary artery revascularization, or&#xD;
             arterial thrombosis within 12 months of start of study drug, inadequately controlled&#xD;
             hypertension, or ventricular tachyarrhythmias requiring ongoing treatment.&#xD;
&#xD;
          -  QTc ≥450 msec or subjects with a history of risk factors for Torsades de Pointes.&#xD;
&#xD;
          -  Stroke or transient ischemic attack within 12 months of trial entry.&#xD;
&#xD;
          -  Clinically significant impaired renal or hepatic function.&#xD;
&#xD;
          -  Presence of active gastrointestinal (GI) disease or other condition that will&#xD;
             interfere significantly with the absorption, distribution, metabolism, or excretion of&#xD;
             CM082.&#xD;
&#xD;
          -  Serious active infection, other serious medical condition or any other condition that&#xD;
             would impair the ability of the subject to administer the investigational drug or to&#xD;
             adhere to the study protocol requirements.&#xD;
&#xD;
          -  Presence of any condition which, in the judgment of the investigator, would prevent&#xD;
             the subject from completing the study.&#xD;
&#xD;
          -  Need to take any medicine that is a strong inhibitor or inducer of CYP3A4.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Tongren Hospital，Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chendu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>May 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorolanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

